{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:00:55Z","timestamp":1760061655238,"version":"3.41.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.7759\/cureus.89086","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T02:50:15Z","timestamp":1753930215000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor"],"prefix":"10.7759","author":[{"given":"Mayuka","family":"Fukata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Omura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt E","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013, 381:320-32. 10.1016\/S0140-6736(12)61140-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad H","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, et al.. Bullous pemphigoid. Nat Rev Dis Primers. 2025, 11:12. 10.1038\/s41572-025-00595-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14797","article-title":"Global incidence and prevalence of bullous pemphigoid: A systematic review and meta-analysis","volume":"21","author":"Lu L","year":"2022","unstructured":"Lu L, Chen L, Xu Y, Liu A. Global incidence and prevalence of bullous pemphigoid: A systematic review and meta-analysis. J Cosmet Dermatol. 2022, 21:4818-35. 10.1111\/jocd.14797","journal-title":"J Cosmet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0804","article-title":"Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases","volume":"34","author":"Pasmatzi E","year":"2011","unstructured":"Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011, 34:e133. 10.2337\/dc11-0804","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin","volume":"26","author":"Skandalis K","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012, 26:249-53. 10.1111\/j.1468-3083.2011.04062.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid","volume":"10","author":"Tasanen K","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. Front Immunol. 2019, 10:1238. 10.3389\/fimmu.2019.01238","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011267","article-title":"Immunity and Coagulation in COVID-19","volume":"25","author":"Avdonin PP","year":"2024","unstructured":"Avdonin PP, Blinova MS, Serkova AA, Komleva LA, Avdonin PV. Immunity and Coagulation in COVID-19. Int J Mol Sci. 2024, 25:10.3390\/ijms252011267","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5575111","article-title":"New-Onset Bullous Pemphigoid in a COVID-19 Patient","volume":"2021","author":"Olson N","year":"2021","unstructured":"Olson N, Eckhardt D, Delano A. New-Onset Bullous Pemphigoid in a COVID-19 Patient. Case Rep Dermatol Med. 2021, 2021:5575111. 10.1155\/2021\/5575111","journal-title":"Case Rep Dermatol Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-00971-8","article-title":"Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity","volume":"3","author":"De Medeiros VL","year":"2021","unstructured":"De Medeiros VL, Monteiro-Neto AU, Fran\u00e7a DD, Castelo Branco R, de Miranda Coelho \u00c9O, Takano DM. Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity. SN Compr Clin Med. 2021, 3:1768-72. 10.1007\/s42399-021-00971-8","journal-title":"SN Compr Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan A","year":"2021","unstructured":"Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021, 20:102792. 10.1016\/j.autrev.2021.102792","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19373","article-title":"Bullous pemphigoid with autoantibodies against full-length BP180 protein after COVID-19 infection","volume":"37","author":"Oya K","year":"2023","unstructured":"Oya K, Kakurai M, Izumi K, Ishii N, Nomura T. Bullous pemphigoid with autoantibodies against full-length BP180 protein after COVID-19 infection. J Eur Acad Dermatol Venereol. 2023, 37:e1266-7. 10.1111\/jdv.19373","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963401","article-title":"The significance of preclinical anti-BP180 autoantibodies","volume":"13","author":"Mai Y","year":"2022","unstructured":"Mai Y, Izumi K, Mai S, Ujiie H. The significance of preclinical anti-BP180 autoantibodies. Front Immunol. 2022, 13:963401. 10.3389\/fimmu.2022.963401","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/BF00577838","article-title":"A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide","volume":"7","author":"Hopsu-Havu VK","year":"1966","unstructured":"Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966, 7:197-201. 10.1007\/BF00577838","journal-title":"Histochemie"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830863","article-title":"Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease","volume":"13","author":"Huang J","year":"2022","unstructured":"Huang J, Liu X, Wei Y, et al.. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease. Front Immunol. 2022, 13:830863. 10.3389\/fimmu.2022.830863","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1120","article-title":"Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo","volume":"181","author":"Forssmann U","year":"2008","unstructured":"Forssmann U, Stoetzer C, Stephan M, et al.. Inhibition of CD26\/dipeptidyl peptidase IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol. 2008, 181:1120-7. 10.4049\/jimmunol.181.2.1120","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_831_21","article-title":"Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions","volume":"10","author":"Shukla AK","year":"2021","unstructured":"Shukla AK, Jhaj R, Misra S, Ahmed SN, Nanda M, Chaudhary D. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care. 2021, 10:3303-8. 10.4103\/jfmpc.jfmpc_831_21","journal-title":"J Family Med Prim Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_659_22","article-title":"Synergistic Effect of Teneligliptin in a Case of New-Onset Bullous Pemphigoid Post Covid-19 Infection","volume":"67","author":"Pareek S","year":"2022","unstructured":"Pareek S, Mohta A, Barsiwal S, Meena S. Synergistic Effect of Teneligliptin in a Case of New-Onset Bullous Pemphigoid Post Covid-19 Infection. Indian J Dermatol. 2022, 67:794-5. 10.4103\/ijd.ijd_659_22","journal-title":"Indian J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17356","article-title":"Development of bullous pemphigoid with autoantibodies against full-length BP180 following COVID-19 infection","volume":"51","author":"Fujita Y","year":"2024","unstructured":"Fujita Y, Nakagawa Y, Hatano Y, Koguchi-Yoshioka H, Izumi K, Fujimoto M. Development of bullous pemphigoid with autoantibodies against full-length BP180 following COVID-19 infection. J Dermatol. 2024, 51:e433-4. 10.1111\/1346-8138.17356","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391682-a-case-of-bullous-pemphigoid-triggered-by-covid-19-infection-in-a-patient-receiving-a-dipeptidyl-peptidase-4-inhibitor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T02:50:20Z","timestamp":1753930220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391682-a-case-of-bullous-pemphigoid-triggered-by-covid-19-infection-in-a-patient-receiving-a-dipeptidyl-peptidase-4-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.89086","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}